Outcome of Board Meeting held on 28th May 2025
MODINATUR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Modi Naturals Ltd's board approved audited financial results for Q4 FY25 and full year ended 31 March 2025, with the statutory auditor (Doogar & Associates) issuing an unmodified (unqualified) opinion on both standalone and consolidated results. On a consolidated basis, revenue from operations surged to ₹662.91 crore from ₹399.82 crore in FY24, a rise of about 66%, while the company swung from a net loss of ₹1.38 crore in FY24 to a net profit of ₹31.03 crore in FY25. Consolidated EPS jumped to ₹23.25 from a negative ₹0.92. On a standalone basis, full-year revenue dipped roughly 5.5% to ₹338.01 crore, but profit after tax rose sharply to ₹7.65 crore from ₹0.91 crore. Q4 standalone revenue grew about 23.5% year-on-year to ₹104.62 crore, though the quarter closed with a small standalone loss of ₹0.09 crore due to a higher tax provision. Operating cash flow turned strongly positive at ₹48.79 crore (consolidated) versus a negative print last year, supported by a one-time GST input credit release at the subsidiary (Modi Biotech).
Strong consolidated turnaround driven by the subsidiary's recovery and operational stabilisation is a clear positive for shareholders. However, the standalone business still shows a shrinking top line and a Q4 loss, so the strength is largely coming from the subsidiary rather than the parent's core branded/bulk oil business, which may limit re-rating until standalone growth re-emerges.